JP2023116489A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023116489A5 JP2023116489A5 JP2023084119A JP2023084119A JP2023116489A5 JP 2023116489 A5 JP2023116489 A5 JP 2023116489A5 JP 2023084119 A JP2023084119 A JP 2023084119A JP 2023084119 A JP2023084119 A JP 2023084119A JP 2023116489 A5 JP2023116489 A5 JP 2023116489A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- dose
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762545393P | 2017-08-14 | 2017-08-14 | |
| US62/545,393 | 2017-08-14 | ||
| JP2019572820A JP7285222B2 (ja) | 2017-08-14 | 2018-08-14 | 副腎皮質刺激ホルモン放出因子受容体拮抗薬 |
| PCT/US2018/046707 WO2019036472A1 (en) | 2017-08-14 | 2018-08-14 | CORTICOTROPIN RELEASE FACTOR RECEPTOR ANTAGONISTS |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019572820A Division JP7285222B2 (ja) | 2017-08-14 | 2018-08-14 | 副腎皮質刺激ホルモン放出因子受容体拮抗薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023116489A JP2023116489A (ja) | 2023-08-22 |
| JP2023116489A5 true JP2023116489A5 (https=) | 2023-10-26 |
| JP7720354B2 JP7720354B2 (ja) | 2025-08-07 |
Family
ID=65362465
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019572820A Active JP7285222B2 (ja) | 2017-08-14 | 2018-08-14 | 副腎皮質刺激ホルモン放出因子受容体拮抗薬 |
| JP2023084119A Active JP7720354B2 (ja) | 2017-08-14 | 2023-05-22 | 副腎皮質刺激ホルモン放出因子受容体拮抗薬 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019572820A Active JP7285222B2 (ja) | 2017-08-14 | 2018-08-14 | 副腎皮質刺激ホルモン放出因子受容体拮抗薬 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210137935A1 (https=) |
| EP (1) | EP3630763A4 (https=) |
| JP (2) | JP7285222B2 (https=) |
| KR (1) | KR102644781B1 (https=) |
| CN (1) | CN110997667A (https=) |
| AR (1) | AR112471A1 (https=) |
| AU (3) | AU2018318990B2 (https=) |
| BR (1) | BR112020002966A2 (https=) |
| CA (1) | CA3064445A1 (https=) |
| EA (1) | EA202090321A1 (https=) |
| MX (2) | MX2019015318A (https=) |
| TW (2) | TWI803504B (https=) |
| WO (1) | WO2019036472A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015112642A1 (en) | 2014-01-21 | 2015-07-30 | Neurocrine Biosciences, Inc. | Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia |
| CN118845788A (zh) | 2017-08-14 | 2024-10-29 | 云杉生物科学公司 | 促肾上腺皮质激素释放因子受体拮抗剂 |
| EA202090321A1 (ru) * | 2017-08-14 | 2020-09-24 | Спрюс Биосайнсес, Инк. | Антагонисты рецептора кортикотропин-рилизинг фактора |
| EP4438124A3 (en) | 2018-04-27 | 2024-12-18 | Spruce Biosciences, Inc. | Methods for treating testicular and ovarian adrenal rest tumors |
| CA3121920A1 (en) | 2018-12-07 | 2020-06-11 | Neurocrine Biosciences, Inc. | Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia |
| TW202116324A (zh) * | 2019-07-19 | 2021-05-01 | 美商雲杉生物科技股份有限公司 | 治療先天性腎上腺增生之方法 |
| JP7623365B2 (ja) | 2019-09-27 | 2025-01-28 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | Ｃｒｆ受容体アンタゴニストおよび使用方法 |
| BR112023002497A2 (pt) * | 2020-08-12 | 2023-05-02 | Spruce Biosciences Inc | Métodos e composições para tratamento da síndrome dos ovários policísticos |
| JP2023540223A (ja) * | 2020-08-26 | 2023-09-22 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | Ｃｒｆ受容体アンタゴニストおよび使用方法 |
| US11708372B2 (en) | 2021-11-19 | 2023-07-25 | Spruce Biosciences, Inc. | Crystalline composition of tildacerfont and methods of use and preparation thereof |
| WO2025188842A1 (en) * | 2024-03-08 | 2025-09-12 | Spruce Biosciences, Inc. | Amorphous solid dispersion of tildacerfont formulations |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3356291B2 (ja) * | 1996-02-07 | 2002-12-16 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｃｒｆレセプター拮抗薬としてのピラゾロピリミジン類 |
| IL137019A (en) * | 1998-01-28 | 2010-11-30 | Du Pont Pharm Co | 2,7 - dimethyl - 4 - (substituted amino) - 8 - arylpyrazolo [1,5-a] triazine derivatives and pharmaceutical compositions containing them |
| EP1049699B1 (en) * | 1998-01-28 | 2004-04-21 | Bristol-Myers Squibb Pharma Company | Pyrazolotriazines as crf antagonists |
| JP2003516353A (ja) * | 1999-12-08 | 2003-05-13 | ファルマシア コーポレイション | ヴァルデコキシブ組成物 |
| WO2005079868A2 (en) * | 2004-02-13 | 2005-09-01 | Sb Pharmco Puerto Rico Inc | Crf receptor antagonists, their preparations, their pharmaceutical composition and their uses |
| AU2006227300B2 (en) * | 2005-03-21 | 2012-02-02 | Eli Lilly And Company | Imidazopyridazine compounds |
| AU2007297481B2 (en) * | 2006-09-20 | 2012-03-08 | Eli Lilly And Company | Thiophene pyrazolopyrimidine compounds |
| EP2094709B1 (en) * | 2006-09-20 | 2010-09-15 | Eli Lilly And Company | Thiazole pyrazolopyrimidines as crf1 receptor antagonists |
| WO2010039678A1 (en) * | 2008-10-02 | 2010-04-08 | Eli Lilly And Company | Thiazolyl-pyrazolopyrimidine compounds as synthetic intermediates and related synthetic processes |
| EA202090321A1 (ru) | 2017-08-14 | 2020-09-24 | Спрюс Биосайнсес, Инк. | Антагонисты рецептора кортикотропин-рилизинг фактора |
-
2018
- 2018-08-14 EA EA202090321A patent/EA202090321A1/ru unknown
- 2018-08-14 TW TW107128345A patent/TWI803504B/zh active
- 2018-08-14 AR ARP180102314 patent/AR112471A1/es unknown
- 2018-08-14 KR KR1020207005534A patent/KR102644781B1/ko active Active
- 2018-08-14 MX MX2019015318A patent/MX2019015318A/es unknown
- 2018-08-14 US US16/639,540 patent/US20210137935A1/en not_active Abandoned
- 2018-08-14 TW TW112117030A patent/TW202400179A/zh unknown
- 2018-08-14 BR BR112020002966-1A patent/BR112020002966A2/pt not_active Application Discontinuation
- 2018-08-14 CA CA3064445A patent/CA3064445A1/en active Pending
- 2018-08-14 CN CN201880038596.0A patent/CN110997667A/zh active Pending
- 2018-08-14 AU AU2018318990A patent/AU2018318990B2/en not_active Ceased
- 2018-08-14 EP EP18846043.0A patent/EP3630763A4/en active Pending
- 2018-08-14 WO PCT/US2018/046707 patent/WO2019036472A1/en not_active Ceased
- 2018-08-14 JP JP2019572820A patent/JP7285222B2/ja active Active
-
2019
- 2019-12-16 MX MX2022015858A patent/MX2022015858A/es unknown
-
2023
- 2023-03-20 AU AU2023201703A patent/AU2023201703B2/en not_active Ceased
- 2023-05-22 JP JP2023084119A patent/JP7720354B2/ja active Active
-
2024
- 2024-12-16 AU AU2024278470A patent/AU2024278470A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023116489A5 (https=) | ||
| JP6875407B2 (ja) | Ｊａｋキナーゼ阻害剤またはその薬剤的に許容される塩を含有する医薬組成物 | |
| US12102637B2 (en) | Pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis | |
| RU2016122609A (ru) | Составы соединений азаиндола | |
| JP2017525712A5 (https=) | ||
| US20170095453A1 (en) | Low Dose Pharmaceutical Composition | |
| RU2011123876A (ru) | Антисмысловые композиции и способы их получения и применения | |
| US20190054088A1 (en) | Pharmaceutical Formulations for Treating Endometriosis, Uterine Fibroids, Polycystic Ovary Syndrome or Adenomyosis | |
| JP2012518002A5 (https=) | ||
| JP2006527195A (ja) | トリプタンおよびｎｓａｉｄを含む組成物 | |
| WO2012164578A1 (en) | Compositions and methods for preparing immediate release formulations of nilotinib | |
| US20160184268A1 (en) | Compositions of eltrombopag | |
| TW201442712A (zh) | 有機化合物之調配物 | |
| HRP20151051T1 (hr) | Formulacije src/abl inhibitora | |
| CN105744930A (zh) | 包含他达拉非和氨氯地平的复合制剂 | |
| JP2024009815A (ja) | アキシチニブを含有する医薬組成物 | |
| WO2014058046A1 (ja) | カルシウム拮抗薬／アンジオテンシンｉｉ受容体拮抗薬含有医薬製剤 | |
| WO2013119607A2 (en) | Modified release formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione | |
| CN104487057A (zh) | 波生坦控释口服制剂 | |
| CN112263581A (zh) | 一种治疗pe和ed的双层片复方制剂及其制备方法 | |
| JP2010516712A5 (https=) | ||
| KR20150049853A (ko) | 다폭세틴 산부가염 및 염기성 약물을 함유하는 경구투여용 복합제제 | |
| EP4398910A1 (en) | A capsule formulation comprising macitentan | |
| WO2023038600A1 (en) | A capsule formulation comprising macitentan | |
| RU2024101683A (ru) | Фармацевтическая композиция, содержащая напроксен и парацетамол |